Evidence map›Paper›PMID 36407196›Full record

ArticleCureus2022

Evaluation of Knowledge of Immunotherapy Toxicities Among Emergency Physicians in Riyadh, Saudi Arabia.

Arwa Alahmadi, Haya Altamimi, Mohammed Algarni

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Arwa AlahmadiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Haya AltamimiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Mohammed AlgarniDepartment of Oncology, National Guard Health Affairs, Riyadh, SAU.
King Saud bin Abdulaziz University for Health Sciences · SANational Guard Health Affairs · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Immunotherapy is considered a new modality in the treatment of cancer with emerging different toxicity profiles. It is essential for healthcare practitioners to be aware of these side effects. Emergency medicine physicians are first-line health providers and should have the required knowledge and understanding of immunotherapy-related adverse effects to be able to identify and manage such patients. The study aimed to assess the level of knowledge of immunotherapy toxicity among emergency medicine physicians in Riyadh. Methods This cross-sectional study was conducted at the largest emergency medicine training centers in Riyadh. In total, 106 emergency medicine physicians participated. The questionnaire contained multiple-choice questions that assessed the knowledge and management of immunotherapy-related toxicities. Results The majority of the participants were male residents. The response rate varied for the selected training centers. Regarding the level of knowledge regarding the toxic side effects of cancer immunotherapy, the majority were likely to choose "I don't know." Conclusion This study, in support of the literature, revealed the gap in knowledge of the basic principles of cancer immunotherapy, despite increasing uses and indications of immunotherapy. The findings indicate the need for non-oncologist health practitioners, including emergency physicians, to enhance their knowledge of immunotherapy-related adverse events in order to improve their clinical decision-making skills.

Indexed as

cancer immunotherapyeducationemergency physiciansimmunotherapy toxicityknowledge

Identifiers

PMID36407196
PMCPMC9662255
OpenAlexW4306293774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.